Clinical trials: Proteinuric Diseases
Proteinuria
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of graft failure.
- Trial name
- NCT02327403
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Gestational Hypertension
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
The investigators do not know which approach to treatment of non-severe high blood pressure in pregnancy is better for women and babies.
- Trial name
- NCT01192412
- Testing
- Intervention is blood pressure management approach, Intervention is blood pressure management approach.
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 987 people
- Sponsor
- University of British Columbia
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Hypertension, Chronic Kidney Disease
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Purpose of this study 1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional…
- Conditions
- Hypertension, Chronic Kidney Disease, Microalbuminuria
- Trial name
- ESPECIAL (NCT01552954)
- Testing
- Intensive education of low salt diet
- Where
- 7 sites in South Korea
- Volunteers
- 269 people
- Sponsor
- Seoul National University Bundang Hospital